Drug Trial Radar · NCT02075281
Effect of LAPS-Exendin on Body Weight in Obese Population
Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
297
Actual
Start
Feb 2014
Primary completion
Jan 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Conditions
- Obesity
Interventions
HM11260CBiological
Glucagon-like peptide-1 analogue
PlaceboBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in body weight at 20 weeksTime frame: 20 weeks from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hanmi pharmaceutical
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.